150 related articles for article (PubMed ID: 36709123)
21. [Characteristics and outcomes of primary angiosarcoma].
Zhang ZY; Cheng YJ; Gong XL; Ge YP; Bai CM; Wang XJ; Miao Q; Zhang FQ
Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):693-697. PubMed ID: 31550860
[No Abstract] [Full Text] [Related]
22. [Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer].
Li N; Jin ZL; Liu ZJ; Wang J; Li K
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):937-42. PubMed ID: 22340106
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
24. Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
Huang D; Cui P; Huang Z; Wu Z; Tao H; Zhang S; Xiang R; Hu Y
J Cancer Res Clin Oncol; 2021 Mar; 147(3):881-891. PubMed ID: 32909095
[TBL] [Abstract][Full Text] [Related]
25. Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study.
Tian Z; Dong S; Yang Y; Gao S; Yang Y; Yang J; Zhang P; Wang X; Yao W
BMC Cancer; 2022 Jan; 22(1):56. PubMed ID: 35022029
[TBL] [Abstract][Full Text] [Related]
26. Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study.
Watson S; Verret B; Ropert S; Adam J; Bahleda R; Briand S; Cavalcanti A; Chamseddine AN; Court C; Fadel E; Faron M; Haddag-Miliani L; Henon C; Pechoux CL; Levy A; Mercier O; Ngo C; Honoré C; Cesne AL; Mir O
Cancer Med; 2023 Feb; 12(3):3160-3166. PubMed ID: 35971325
[TBL] [Abstract][Full Text] [Related]
27. Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives.
Tian Z; Feng Y; Yang Y; Liu X; Qu G; Yang Y; Wang X; Wang J; Zhang P; Yao W
Front Pharmacol; 2024; 15():1335054. PubMed ID: 38362151
[No Abstract] [Full Text] [Related]
28. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
Front Immunol; 2022; 13():801909. PubMed ID: 35309350
[TBL] [Abstract][Full Text] [Related]
29. Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Bang YJ; Xu RH; Chin K; Lee KW; Park SH; Rha SY; Shen L; Qin S; Xu N; Im SA; Locker G; Rowe P; Shi X; Hodgson D; Liu YZ; Boku N
Lancet Oncol; 2017 Dec; 18(12):1637-1651. PubMed ID: 29103871
[TBL] [Abstract][Full Text] [Related]
30. The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patients.
Tanaka M; Hattori Y; Ishii T; Tohnai R; Itoh S; Kawa Y; Kono Y; Urata Y; Satouchi M
Respir Investig; 2020 Jul; 58(4):269-274. PubMed ID: 32111518
[TBL] [Abstract][Full Text] [Related]
31. Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer.
Zhai X; Jing X; Li J; Tian Y; Xu S; Wang M; Zhu H
Front Oncol; 2020; 10():556275. PubMed ID: 33102221
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticle albumin-bound paclitaxel in elder patients with advanced squamous non-small-cell lung cancer: A retrospective study.
Liu Y; Dong Y; Zhu H; Jing W; Guo H; Yu J
Cancer Med; 2020 Feb; 9(4):1365-1373. PubMed ID: 31876976
[TBL] [Abstract][Full Text] [Related]
33. [Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
Zhang WL; Zhou C; Deng YX; Hou ZL; Zhang LJ; Lin JZ; Pan ZZ; Lu ZH; Peng JH
Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jan; 25(1):56-62. PubMed ID: 35067035
[No Abstract] [Full Text] [Related]
34. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P; Italiano A; Piperno-Neumann S; Chevreau C; Penel N; Firmin N; Boudou-Rouquette P; Bertucci F; Balleyguier C; Lebrun-Ly V; Ray-Coquard I; Kalbacher E; Bardet A; Bompas E; Collard O; Isambert N; Guillemet C; Rios M; Archambaud B; Duffaud F;
Lancet Oncol; 2022 Aug; 23(8):1044-1054. PubMed ID: 35835135
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer.
Yu W; Tao Q; Zhang Y; Yi F; Feng L
J Oncol; 2021; 2021():9959946. PubMed ID: 34603452
[TBL] [Abstract][Full Text] [Related]
36. Primary angiosarcoma of bone: a retrospective analysis of 60 patients from 2 institutions.
Palmerini E; Maki RG; Staals EL; Alberghini M; Antonescu CR; Ferrari C; Ruggieri P; Mavrogenis A; Bertoni F; Cesari M; Paioli A; Marchesi E; Picci P; Ferrari S
Am J Clin Oncol; 2014 Dec; 37(6):528-34. PubMed ID: 23466575
[TBL] [Abstract][Full Text] [Related]
37. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas.
Italiano A; Cioffi A; Penel N; Levra MG; Delcambre C; Kalbacher E; Chevreau C; Bertucci F; Isambert N; Blay JY; Bui B; Antonescu C; D'Adamo DR; Maki RG; Keohan ML
Cancer; 2012 Jul; 118(13):3330-6. PubMed ID: 22045619
[TBL] [Abstract][Full Text] [Related]
38. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
39. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
40. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
